Intelligence · Clinical Pipeline
Hospital Authority Pipeline
All ClinicalTrials.gov programs at Hospital Authority — phase, modality, and trial IDs.
- Programs
- 322
Quick answer
Hospital Authority has 322 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Ivonescimab 20 mg/kg
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
1 trial -
Lenalidomide [Leavdo®]
Hospital Authority, Hong Kong
Antibiotics-unresponsive MALT Lymphoma
1 trial -
Liposorber LA-15 System
Hospital Authority, Hong Kong
Cholesterol Embolism
1 trial -
MLC901
Hospital Authority, Hong Kong
Alzheimer Disease
1 trial -
MSC and PRP
Hospital Authority, Hong Kong
Type 1 Diabetes Mellitus
1 trial -
Morphine
Hospital Authority, Hong Kong
Respiratory Depression
1 trial -
NK cells
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial -
Osteosheet(r)
Hospital Authority, Hong Kong
Orbital Trauma
1 trial -
Oxaliplatin, 5FU, leucovorin
Hospital Authority, Hong Kong
Biliary Cancer Metastatic
1 trial -
Pemebit
Hospital Authority, Hong Kong
Adenocarcinoma
1 trial -
Placebo
Hospital Authority, Hong Kong
STOMACH NEOPLASM
1 trial -
Quadriceps strength training
Hospital Authority, Hong Kong
Patellofemoral Pain Syndrome
1 trial -
Radiation: Radiation Therapy;Biological: Personalized tumor peptide vaccine
Hospital Authority, Hong Kong
Advanced Tumors
1 trial -
Radio-guided sentinel node biopsy
Hospital Authority, Hong Kong
Cancer of the Breast
1 trial -
Repigel
Hospital Authority, Hong Kong
Acne
1 trial -
Romiplostim N01
Hospital Authority, Hong Kong
Chemotherapy-induced Thrombocytopenia
1 trial -
SHR-1210
Hospital Authority, Hong Kong
Renal Cell Carcinoma
1 trial -
SNUBH-NM-333(18F)
Hospital Authority, Hong Kong
Alzheimer Disease
1 trial -
SS-1
Hospital Authority, Hong Kong
Sjögren's Syndrome
1 trial -
Sarcosine and D-serine
Hospital Authority, Hong Kong
Schizophrenias
1 trial -
Sargramostim
Hospital Authority, Hong Kong
COVID
1 trial -
Sargramostim
Hospital Authority, Hong Kong
Pulmonary Alveolar Proteinosis, Autoimmune
1 trial -
Selinexor
Hospital Authority, Hong Kong
Acute Myeloid Leukemia, Adult
1 trial -
Silodosin
Hospital Authority, Hong Kong
Premature Ejaculation
1 trial -
Spironolactone 25mg
Hospital Authority, Hong Kong
Atrial Fibrillation
1 trial -
TS-1 with cisplatin
Hospital Authority, Hong Kong
Recurrent Gastric Cancer
1 trial -
Testosterone Enanthate 100 MG/ML Injectable Solution
Hospital Authority, Hong Kong
Castration-resistant Prostate Cancer
1 trial -
Tislelizumab
Hospital Authority, Hong Kong
Pancreatic Neoplasms
1 trial -
Tocilizumab
Hospital Authority, Hong Kong
Adamantinomatous Craniopharyngioma
1 trial -
Transplantation of Autologous stem cell [MNCs] .
Hospital Authority, Hong Kong
Spinal Cord Injury.
1 trial -
Trastuzumab in Combination with TS-ONE and cisplatin
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
Umbilical Cord Blood Infusion
Hospital Authority, Hong Kong
Cerebral Palsy
1 trial -
Ursodeoxycholic acid
Hospital Authority, Hong Kong
Hepatitis D
1 trial -
a standardized physical therapy program
Hospital Authority, Hong Kong
Frozen Shoulder
1 trial -
acupuncture
Hospital Authority, Hong Kong
Peripheral Neuropathy Grade 2 or Greater
1 trial -
artesunate
Hospital Authority, Hong Kong
Colorectal Cancer
1 trial -
autologous adipose-derived mesenchymal stem cell transplantation
Hospital Authority, Hong Kong
Aging Problems
1 trial -
combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
docetaxel and ketoconazole
Hospital Authority, Hong Kong
Metastatic Breast Cancer
1 trial -
doxorubicin, docetaxel
Hospital Authority, Hong Kong
Metastatic Breast Cancer
1 trial -
nitric oxide gel
Hospital Authority, Hong Kong
Neuropathic Pain
1 trial -
paclitaxel/carboplatin/lapatinib
Hospital Authority, Hong Kong
ErbB2-Positive Stage I-III Breast Cancer
1 trial -
pembrolizumab
Hospital Authority, Hong Kong
Locally Recurrent Cancer
1 trial -
real-tDCS with MI-BCI
Hospital Authority, Hong Kong
Stroke
1 trial -
remicade (anti tumor necrosis factor inhibitor)
Hospital Authority, Hong Kong
Takayasu's Arteritis
1 trial -
AZD5363+Olaparib+Durvalumab
Hospital Authority, Hong Kong
Solid Tumor, Adult
1 trial -
Autologous Natural Killer Cell Therapy
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial -
Biological: PD-1
Hospital Authority, Hong Kong
Advanced Solid Tumor
1 trial
Frequently asked questions
How many pipeline programs does Hospital Authority have?
322 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs